【摘要】：目的探究人參皂苷對小鼠晚期乳腺癌模型的抑瘤作用。方法小鼠適應(yīng)性飼養(yǎng)1周后將4T1乳腺癌細(xì)胞懸液1 m L(1.0×1010L-1)接種于右胸部皮下建立晚期乳腺癌模型。30只BALB/c小鼠晚期乳腺癌模型隨機分為模型組、環(huán)磷酰胺組、人參皂苷低劑量組、人參皂苷中劑量組和人參皂苷高劑量組,每組6只。環(huán)磷酰胺組小鼠給予環(huán)磷酰胺2 mg·kg-1,腹腔注射,隔日1次;人參皂苷低、中、高劑量組小鼠分別給予0.5、1.0、2.0 mg·kg-1的人參皂苷灌胃;模型組小鼠給予2 m L·kg-1的無菌生理鹽水灌胃;灌胃均每日1次,連續(xù)4周。蘇木精-伊紅染色觀察各組小鼠乳腺癌組織的病理改變,并比較各組小鼠的癌瘤質(zhì)量、體積,抑瘤率,肺轉(zhuǎn)移結(jié)節(jié)數(shù)及腫瘤轉(zhuǎn)移抑制率。結(jié)果環(huán)磷酰胺組和人參皂苷低、中、高劑量組小鼠癌瘤質(zhì)量和體積均顯著小于模型組(P0.05),抑瘤率顯著高于模型組(P0.05);人參皂苷中劑量組小鼠癌瘤質(zhì)量、體積及抑瘤率與環(huán)磷酰胺組比較差異均無統(tǒng)計學(xué)意義(P0.05);人參皂苷高劑量組小鼠癌瘤質(zhì)量和體積均顯著小于環(huán)磷酰胺組(P0.05),抑瘤率顯著高于環(huán)磷酰胺組(P0.05);人參皂苷中、高劑量組小鼠癌瘤質(zhì)量和體積均顯著小于人參皂苷低劑量組(P0.05),抑瘤率顯著高于人參皂苷低劑量組(P0.05);人參皂苷高劑量組小鼠癌瘤質(zhì)量和體積均小于人參皂苷中劑量組,抑瘤率高于人參皂苷中劑量組,但差異均無統(tǒng)計學(xué)意義(P0.05)。環(huán)磷酰胺組和人參皂苷低、中、高劑量組小鼠肺轉(zhuǎn)移結(jié)節(jié)數(shù)顯著少于模型組(P0.05),肺轉(zhuǎn)移抑制率顯著高于模型組(P0.05);人參皂苷中劑量組小鼠肺轉(zhuǎn)移結(jié)節(jié)數(shù)及肺轉(zhuǎn)移抑制率與環(huán)磷酰胺組比較差異均無統(tǒng)計學(xué)意義(P0.05);人參皂苷高劑量組小鼠肺轉(zhuǎn)移結(jié)節(jié)數(shù)顯著少于環(huán)磷酰胺組(P0.05),肺轉(zhuǎn)移抑制率顯著高于環(huán)磷酰胺組(P0.05);人參皂苷中、高劑量組小鼠肺轉(zhuǎn)移結(jié)節(jié)數(shù)顯著少于人參皂苷低劑量組(P0.05),肺轉(zhuǎn)移抑制率顯著高于人參皂苷低劑量組(P0.05);人參皂苷中、高劑量組小鼠肺轉(zhuǎn)移結(jié)節(jié)數(shù)及肺轉(zhuǎn)移抑制率比較差異均無統(tǒng)計學(xué)意義(P0.05)。結(jié)論人參皂苷能夠顯著抑制小鼠乳腺癌的發(fā)生、發(fā)展和轉(zhuǎn)移。
[Abstract]:Objective to investigate the inhibitory effect of ginsenoside on advanced breast cancer in mice. Methods A model of advanced breast cancer was established by inoculating 4T1 breast cancer cell suspension 1 m L (1.0 脳 1010L-1 into the right chest subcutaneously in mice for one week. Thirty BALB/c mice with advanced breast cancer were randomly divided into model group and cyclophosphamide group. Ginsenoside low dose group, ginsenoside medium dose group and ginsenoside high dose group, 6 rats in each group. Mice in the cyclophosphamide group were intraperitoneally injected with cyclophosphamide for 2 mg kg-1, once every other day. The mice in the model group were given 2 mL kg-1 aseptic saline once a day for 4 weeks. The pathological changes of breast cancer in each group were observed by hematoxylin-eosin staining. The tumor mass, volume, tumor inhibition rate, the number of metastatic nodules of lung and the tumor metastasis inhibition rate were compared in each group. Results the tumor mass and volume of mice in the cyclophosphamide group and ginsenoside group were significantly lower than those in the model group (P0.05), and the tumor inhibition rate was significantly higher in the middle and high dose groups than in the model group (P0.05). There was no significant difference in tumor quality, volume and tumor inhibition rate between middle dose group and cyclophosphamide group (P0.05). The tumor mass and volume of high-dose ginsenoside group were significantly lower than that of cyclophosphamide group (P0.05), and the tumor inhibition rate was significantly higher than that of cyclophosphamide group (P0.05). In the ginsenoside group, the tumor mass and volume in the high-dose group were significantly lower than those in the low-dose group (P0.05), and the tumor inhibition rate was significantly higher than that in the low-dose group (P0.05). The tumor mass and volume of high dose group of ginsenoside were lower than that of middle dose group of ginsenoside, and the inhibition rate of tumor was higher than that of middle dose group of ginsenoside, but the difference was not statistically significant (P0.05). Cyclophosphamide group and ginsenoside group were low, the number of lung metastasis nodules in high dose group was significantly lower than that in model group (P0.05), the inhibition rate of lung metastasis was significantly higher than that of model group (P0.05). There was no significant difference in the number of pulmonary metastasis nodules and the inhibition rate of lung metastasis between the middle dose group and cyclophosphamide group (P0.05). The number of metastatic nodules in high dose group was significantly lower than that in cyclophosphamide group (P0.05), and the inhibition rate of lung metastasis was significantly higher than that of cyclophosphamide group (P0.05). In the ginsenoside group, the number of pulmonary metastasis nodules in the high-dose group was significantly less than that in the low-dose group (P0.05), and the inhibitory rate of lung metastasis was significantly higher than that in the low-dose group (P0.05). There was no significant difference in the number of pulmonary metastasis nodules and the inhibition rate of lung metastasis in the high dose group (P0.05). Conclusion ginsenoside can significantly inhibit the occurrence, development and metastasis of breast cancer in mice.
【作者單位】： 南昌市第三醫(yī)院乳腺腫瘤科;
【分類號】：R285.5;R-332

【參考文獻】

相關(guān)期刊論文 前8條

1 李紅梅;聶麗娟;霍強;趙素容;馬濤;吳成柱;劉浩;;Hsp90抑制劑i諶縊岫勻橄侔㎝DA-MB-231細(xì)胞增殖、侵襲、遷移的影響[J];南方醫(yī)科大學(xué)學(xué)報;2015年03期

2 黃俊輝;張軼;黃玉婷;張曦蓓;肖佳;;MIF對耐ADM人乳腺癌細(xì)胞MCF-7/ADM體內(nèi)外耐藥逆轉(zhuǎn)作用[J];中南大學(xué)學(xué)報(醫(yī)學(xué)版);2010年06期

3 劉敏;章永紅;顏曉靜;張露蓉;;杉蟾藤成分復(fù)方誘導(dǎo)ER(+)人乳腺癌MCF-7細(xì)胞凋亡的實驗研究[J];南京中醫(yī)藥大學(xué)學(xué)報;2014年03期

4 魏愛書;趙銳;;人參揮發(fā)油的研究進展[J];人參研究;2010年02期

5 呂紅;鄒樂蘭;麻俊超;王珊;劉婷;柯小琴;付劍江;;三白草提取物抗乳腺癌轉(zhuǎn)移作用及其機制研究[J];中國實驗方劑學(xué)雜志;2015年07期

6 彭曉丹;諸夢露;高綠芬;劉婷婷;劉艷;歐陽媛;李若玢;劉禮飛;李譯;劉曉宇;鄭曉鶴;林紹強;;FK228和雷帕霉素協(xié)同促進人乳腺癌細(xì)胞凋亡和細(xì)胞周期阻滯[J];中國病理生理雜志;2015年04期

7 魏家彬;楊帆;王淑秀;;人參皂苷Rg1對1-甲基-4-苯基-1,2,3,6-四氫吡啶誘導(dǎo)的帕金森病小鼠黑質(zhì)酪氨酸蛋白激酶A4表達的影響[J];新鄉(xiāng)醫(yī)學(xué)院學(xué)報;2015年05期

8 李馨剛;;葛根素對乳腺癌細(xì)胞MCF-7增殖及凋亡的影響[J];中國老年學(xué)雜志;2015年15期

【共引文獻】

相關(guān)期刊論文 前10條

1 陳斯?jié)?李玉齊;楊曙;莫賢毅;舒陽春;莫凱嵐;丁穎;陳雪梅;;HSP90抑制劑對食管鱗癌細(xì)胞株TE-1凋亡的影響及作用機制[J];分子影像學(xué)雜志;2015年03期

2 李紅梅;李靜;靳偉;郭星;李楠;馬濤;霍強;吳成柱;;新木脂素的酶法糖基化及抗腫瘤活性[J];南方醫(yī)科大學(xué)學(xué)報;2015年11期

3 易文君;彭靖;張亞杰;付芬芬;鄒瓊燕;唐圓圓;;乳腺癌化學(xué)治療敏感與耐藥組織相關(guān)蛋白表達差異[J];中南大學(xué)學(xué)報(醫(yī)學(xué)版);2013年02期

4 Lijun CAO;Tao XU;Hua ZHAO;Jianhua WEI;Dandan HAN;Rui ZHAO;;Technology of Supercritical CO_2 Extraction of Volatile Oil from RADIX ET RHIZOMA GINSENG[J];Medicinal Plant;2013年08期

5 宋畢清;時開網(wǎng);楊士勇;;米非司酮對胰腺癌細(xì)胞耐藥株P(guān)atu8988/FU的逆轉(zhuǎn)作用[J];現(xiàn)代生物醫(yī)學(xué)進展;2012年01期

6 曹立軍;徐濤;趙花;魏建華;趙銳;韓丹丹;;超臨界CO_2萃取人參揮發(fā)油工藝的研究[J];人參研究;2012年03期

7 趙花;徐濤;曹立軍;魏建華;陳斌;趙銳;;正交實驗優(yōu)化6~㥮溶劑油提取人參揮發(fā)油工藝的研究[J];人參研究;2012年04期

8 劉婷婷;崔海月;王大為;;人參淀粉的基本性質(zhì)[J];食品科學(xué);2013年19期

9 蘇向東;陸啟麗;高琴琴;包海鷹;;獨參湯化學(xué)成分的研究[J];人參研究;2013年04期

10 劉婷婷;劉鴻鋮;樊紅秀;王大為;;人參脂溶性成分提取工藝優(yōu)化及其GCMS分析[J];食品工業(yè)科技;2014年09期

相關(guān)碩士學(xué)位論文 前10條

1 張敏;高速逆流色譜分離純化人參、龍膽中的有效成分[D];長春師范學(xué)院;2011年

2 高寶榮;米非司酮通過上調(diào)Smac促進凋亡逆轉(zhuǎn)卵巢癌耐藥的實驗研究[D];天津醫(yī)科大學(xué);2011年

3 孫艷;人參仿生化提取分離及初步藥效學(xué)研究[D];長春中醫(yī)藥大學(xué);2011年

4 崔芳芳;米非司酮抑制乳腺癌細(xì)胞增殖及促凋亡作用機理的初步研究[D];河南大學(xué);2012年

5 劉宏;不同生境條件下人參中9種酶的活力變化研究[D];長春中醫(yī)藥大學(xué);2012年

6 鄭兵;人參煎劑與人參皂苷對小鼠免疫功能影響的比較研究[D];遼寧中醫(yī)藥大學(xué);2012年

7 王悅;人參農(nóng)藥多殘留檢測方法及農(nóng)藥殘留研究[D];吉林農(nóng)業(yè)大學(xué);2013年

8 張玉婷;人參提取物化學(xué)成分及質(zhì)量研究[D];中國食品藥品檢定研究院;2013年

9 宋喜臣;保肝丸制備工藝及質(zhì)量標(biāo)準(zhǔn)研究[D];吉林大學(xué);2014年

10 牛春穎;蒸參水中揮發(fā)油的提取及性質(zhì)研究[D];長春工業(yè)大學(xué);2014年

【二級參考文獻】

相關(guān)期刊論文 前10條

1 宋長春,馬興元;人參露化學(xué)成分的分析[J];白求恩醫(yī)科大學(xué)學(xué)報;1983年06期

2 馬興元,宋長春,徐景達,曹淑蘭,李念平;人參揮發(fā)油化學(xué)成分的研究[J];白求恩醫(yī)科大學(xué)學(xué)報;1985年04期

3 張偉紅;張西臣;邢沈陽;李澤中;宮鵬濤;李建華;楊舉;倪勁松;;DHRS7對人乳腺癌細(xì)胞MCF-7細(xì)胞周期的影響及其在乳腺癌組織中的表達[J];吉林大學(xué)學(xué)報(醫(yī)學(xué)版);2012年03期

4 安明;趙國君;韋新成;;人參皂苷Rg_1保護心血管和中樞神經(jīng)系統(tǒng)的藥理活性研究進展[J];中國臨床藥理學(xué)雜志;2012年01期

5 方艷秋;齊亞靈;蘆小單;馬寅芙;譚巖;;環(huán)氧合酶2抑制劑NS-398對人肝癌細(xì)胞SMMC-7721增殖與凋亡的影響[J];吉林大學(xué)學(xué)報(醫(yī)學(xué)版);2013年06期

6 吳衛(wèi)平;李俊敏;張博愛;賈延R，

本文編號：2394575